Drug Trial Radar · NCT03250338
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Aug 16, 2018
Primary completion
Apr 3, 2026
Study completion Apr 3, 2026
Sponsor
- Lead sponsor
- Arog Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Interventions
CrenolanibDrug
Crenolanib will be administered orally
CytarabineDrug
HAM regimen FLAG-Ida
MitoxantroneDrug
HAM regimen
Placebo Oral TabletDrug
Placebo will be administered orally
FludarabineDrug
FLAG-Ida regimen
IdarubicinDrug
FLAG-Ida regimen
G-CSFDrug
FLAG-Ida regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: 3 years
Locations
62 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Sacramento, California
UC Davis Comprehensive Cancer Center
Sacramento, California
University of Florida
Gainesville, Florida
University of Chicago
Chicago, Illinois
Kansas University
Kansas City, Kansas
Karmanos Cancer Center
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
Roswell Park Cancer Institute
Buffalo, New York
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
University of Alberta
Edmonton, Alberta, Canada
Hospital Avicenne
Bobigny, France
CHU Grenoble Alpes
Grenoble, France
Hospital Center of Versailles (Le Chesnay)
Le Chesnay, France
Hospital Claude Huriez - Chru Lille
Lille, France
Institut Paoli-Calmettes
Marseille, France
CHU de Nantes - Hôtel Dieu
Nantes, France
University Hospital Nice L'Archet
Nice, France
Hôpital St Louis
Paris, France
CHU de Bordeaux
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
CHU de Poitiers
Poitiers, France
Institut Universitaire du Cancer Toulouse
Toulouse, France
Klinikum Chemnitz gGmbH
Chemnitz, Germany
Technische Universität Dresden
Dresden, Germany
Universitätsklinikum Essen (AöR)
Essen, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Universitätsklinikum Halle (Saale)
Halle, Germany
Universitätsklinikum Münster
Münster, Germany
AOU Policlinico Sant'Orsola-Malpighi
Bologna, Italy
ASST Spedali Civili di Brescia
Brescia, Italy
AOU Careggi
Florence, Italy
IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy
IRCCS San Raffaele Hospital
Milan, Italy
IRCCS Foundation Ca 'Granda Ospedale Maggiore Policlinico
Milan, Italy
Istituto Europeo di Oncologia
Milan, Italy
Aorn Antonio Cardarelli
Naples, Italy
AOU Federico II
Naples, Italy
AOU Maggiore della Carità
Novara, Italy
AO Ospedali Riuniti Villa Sofia-Cervello
Palermo, Italy
AO Ospedali Riuniti Marche Nord
Pesaro, Italy
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.